Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23135159 | 0.92 | — | — | |
| SCHEMBL5463237 | 0.76 | NCF1 (0.30) | NCF1 | |
| SCHEMBL20795823 | 0.76 | — | — | |
| SCHEMBL20842233 | 0.76 | — | — | |
| SCHEMBL125618 | 0.76 | NCF1 (0.50) | NCF1 | |
| SCHEMBL22691891 | 0.76 | MAOB (0.36) | — | |
| SCHEMBL2162286 | 0.76 | JAK2 (0.33) | — | |
| SCHEMBL24197645 | 0.76 | JAK2 (0.33) | — | |
| SCHEMBL13907209 | 0.76 | JAK2 (0.33) | — | |
| SCHEMBL365047 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| US-12478620-B2 | Cyano-substituted cyclic hydrazine derivative and application thereof | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2025-11-25 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173017-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2022-10-27 | — | — | US | disclosed |
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2022-10-27 | — | — | US | disclosed |
| EP-4032888-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2022-07-27 | — | — | EP | disclosed |
| CN-110483514-B | Cyano-substituted cyclic hydrazine derivative and application thereof | 启元生物(杭州)有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021051899-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | 维眸生物科技（上海）有限公司 | 2021-03-25 | — | — | WO | disclosed |
| CN-110483514-A | The ring hydrazine derivate and its application that a kind of cyano replaces | VIVAVISION BIOPHARMA SHANGHAI CO LTD | 2019-11-22 | — | — | CN | disclosed |
| WO-2015022663-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022663-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | WNK1, STK35, CDK1 | NCF1 1080/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | NCF1 1281/4885 |
| US-12478620-B2 | Cyano-substituted cyclic hydrazine derivative and application thereof | WNK1, STK35, CDK1 | NCF1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.